Introduction
The use of smokeless tobacco (ST)-oral snuff or chewing tobacco-increased in popularity in the 1970s and 1980s. Approximately 10 million Americans used ST in the past year; 3 million were less than 21 years of age. ' Among young men, the use of moist snuff has become particularly widespread.2 Smokeless tobacco use results in considerable systemic exposure to nicotine.34 The results of studies of cigarette smokers have led to concern that nicotine may increase the risk of atherosclerotic vascular disease.5 Nicotine may contribute to atherosclerosis by affecting lipid metabolism, coagulation, hemodynamic status, or all three. Smokers have higher levels of low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) cholesterol and lower levels of high-density lipoprotein (HDL) cholesterol than do nonsmokers." Cigarette smoking or the administration of nicotine acutely increases heart rate and blood pressure, although in habitual cigarette smokers blood pressure tends to be lower than in nonsmokers. 9 Circulating leukocytes, primarily neutrophils, are higher in smokers than in nonsmokers, and leukocyte counts return toward nonsmoking levels after smoking cessation."' 11 Neutrophils may generate oxygen-free radicals and other substances that promote thrombosis, and they may accelerate endothelial cell growth, both of which could contribute to the acceleration of atherosclerotic vascular disease. 5 The participants were classified on the basis of their self-reported ST use as nonusers (those who had never used ST or who had used ST in the past but never more frequently than once a month) and users (those who had used ST within the past week). Former users (those who had used ST more than once a month in the past but had not used ST within the previous month) and infrequent current users (those who had used ST within the past month but not within the past week) were excluded from analyses. For any player for whom we had data from both 1988 and 1989, we used only the data from the year for which the data were most complete. If data from both years were equally complete, 1989 data were used for that player.
Data from a total of 477 ST users and 584 nonusers are included in this report.
Blood Pressure and Pulse
After the participants completed the questionnaire, their heart rate and blood pressure were measured twice, several minutes apart, in a sitting position. Systolic blood pressure was recorded at the levelwhen phase 1 Korotkoffsoundswere first heard and diastolic blood pressure was recorded at the beginning of phase 5 with the disappearance of sounds. To avoid the effects of physical activity, we included in our analysis of blood pressure and pulse rates only measurements from individuals who had not come to the examination directly from the playing field.
Biochemical Measurements
Blood was drawn to measure total serum cholesterol; HDL cholesterol; nicotine, cotinine, and caffeine levels; and white blood cell count. Biochemical validation of self-reported ST use included measurement of cotinine (the primary metabolite of nicotine) and thiocyanate (a marker of tobacco smoke exposure) by gas chromatography.17 Low serum cotinine level (< 12 ng/mL) together with normal serum thiocyanate levels (<85 mmol/L) was considered biochemical evidence of nonuse of tobacco.18 This standard, applied in an initial analysis of participants from whom blood was obtained in 1988 and who reported that they neither used ST nor smoked cigarettes, indicated that 95% (357 of 376 for whom blood samples were obtained in 1988) were correctly classified biochemically as nonusers. Given the high accuracy of use status based on self-report and the fact that blood samples were not obtained from all players presented here, the results shown in Tables 1, 2 , and 4 are based on self-report. Serum caffeine was measured simultaneously with nicotine and cotinine; 7-ethyl theophylline, 5-methylnicotine, and 1-methyl-5-(2-pyridyl)-pyrrolidine, respectively, were used as internal standards.
StatisticalAnalysis
Estimated odds ratios were calculated and adjusted for covariates by means of multiple logistic analyses. ' Cotinine, Nicotine, and Caffeine Levels Serum cotinine measurements were obtained in 230 of the current users. Table  3 presents cotinine levels in relation to type and pattems of ST.use. Participants who used snuff had higher adjusted mean serum cotinine than participants who used chewing tobacco (P < .001). Only 1% of the participants who used chewing tobacco, compared with 24% of those who used snuff, had serum cotmiine levels of >250 ng/mL (data not shown). Participants who reported using ST more hours per day, as well as those who reported more recent use, also had higher adjusted mean serum cotinine levels (P < .001). Similar statistically significant results were found for adjusted mean serum nicotine levels (data not shown). Participants who had used ST for more years had higher adjusted mean serum caffeine levels than those who had used ST for a shorter period (P = .03, data not shown).
Cotinine and Nicotine Levels and Cardiovascular Risk Factors
There was no difference in adjusted systolic and diastolic blood pressure, pulse rate, white blood cell count, and total or HDL cholesterol levels between participants who used snuff exclusively and those who used chewing tobacco exclusively (Table 4) . We examined the association between the above measures and serum cotinine and serum nicotine levels, adjusting for age, race, alcohol use, and serum caffeine (data not shown). There was no association between serum cotinine levels and any of these measures. Interestingly, we failed to confirm our previous finding ofa weak inverse association between serum cotinine levels and serum HDL cholesterol levels.'6 However, higher mean serum nicotine levels were associated with higher diastolic blood pressure levels (P = .02), and there was a trend toward higher pulse rates (P = .09), total cholesterol levels (P= .10), and white blood cell counts (P= .15) with higher mean serum nicotine levels.
Discussion
This group of professional baseball players is the largest population of ST users in which nicotine and associated cardiovascular risk factors have been examined. The large sample size and the high prevalence of ST use provided ample power to detect relatively minor effects of ST use on the cardiovascular risk factors studied. Despite this, we did not find differences in systolic and diastolic blood pressure, total and HDL cholesterol, and white blood cell count between ST users and nonusers. These findings are similar to those that we reported after the first year of the studyl6 and contrast with the results of experimental studies of ST users in which ST use throughout the day produced the same cardiovascular effects as cigarette smoking.13 Additionally, we analyzed the effect of ST use on serum nicotine and cotinine levels and their association with cardiovascular risk factors.
Cotinine is the major metabolite of nicotine and has a much longer half-life than nicotine.'2 For these reasons cotinine is widely used as a biochemical marker of average daily intake of nicotine. Determination of serum cotinine, however, is a relatively insensitive way to detect exactly when tobacco was last used. The mean serum cotinine level was 144 ng/mL for snuffusers and 82 ng/mL for chewers. The average cotinine levels for snuff users were similar to those previously reported in a group of college athletes, but were considerably lower than those measured in a research ward study of ST use and cigarette smoking.313 These cotinine levels are also lower than the average level of 300 ng/mL found in cigarette smokers. ' We found an association between higher serum nicotine levels and increased diastolic blood pressure and trends between higher plasma nicotine levels and increased heart rate and white blood cell count. Serum nicotine reflects the recency of tobacco use, and changes in blood pressure, pulse rate, and white blood cell count might reflect a direct pharmacologic response. 12 Our diastolic blood pressure finding is consistent with findings from other studies showing that ST use acutely increases blood pressure.20,21
The smokeless tobacco users in this study drank more alcohol than did nonusers. This finding is similar to those ofother studies of ST use, in both adolescents and adults. 2 We also found that plasma caffeine levels were higher in ST users than nonusers, perhaps reflecting a tendency toward more psychoactive drug use in ST users. Other studies have found that cigarette smokers drink more caffeine-contamiing beverages than do nonsmokers. 23 Thus, future studies of the cardiovascular effects of ST should control for the potentially confounding effects of caffeine and alcohol.
Although 
